Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
The general evaluation of NXSTAGE MEDICAL INCO. (US), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date November 13, 2018, the closing price was USD 2...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NxStage Medical, Inc. (“NxStage” or the “Company”) (NASDAQ:NXTM) stock prior to August 7, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of NxStage to Fresenius Medical Care for US$30 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/NXTM-Info-Request-Form-ma-...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of NxStage Medical, Inc. (NASDAQ GS: NXTM)? Did you purchase any of your shares prior to August 7, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of NxStage Medical, Inc. (“NxStage Medical” or the “Company”) (NASDAQ GS: NXTM) ...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of NxStage Medical, Inc. (“NxStage”) (NASDAQ: NXTM) concerning the acquisition by Fresenius Medical Care. Under the terms of the agreement, valued at approximately $2 billion, NxStage shareholders will only receive $30.00 per NxStage share owned. The consideration is virtually no premium over the 52-week high and significantly lower than at least one analyst’s estima...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NxStage Medical, Inc. (“NxStage” or the “Company”) (NASDAQ: NXTM) stock prior to August 7, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of NxStage to Fresenius Medical Care for US$30 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/NXTM-Info-Request-Form-ma...
Two Directors at Nxstage Medical Inc sold after exercising options/sold 18,497 shares at between 28.010USD and 28.280USD. The significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.